Gabelli Upgrades AngioDynamics (ANGO) to Hold; Announces $372 Mln Acquisition of Navilyst Medical
Tweet
Share
E-mailGet Alerts ANGO Hot Sheet
Price: $15.85 +1.21%
Rating Summary:
8 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
8 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Gabelli upgraded AngioDynamics (NASDAQ: ANGO) from Sell to Hold.
Analyst, Jeff Jonas, said, "Angiodynamics announced plans to acquire Navilyst Medical for $372 million in cash and stock...The combined company will once again move to separate vascular and peripheral salesforces, allowing each to focus on a smaller number of products and call points...However, Navilyst has seen little or no revenue growth recently, as price and volume pressure in fluid management (61% of sales) offsets growth in vascular access (39%)."
"Overall we think this is a strategic and accretive deal for ANGO. This deal also more than offsets the loss of the LC Bead distribution agreement and does not preclude the company from future tuck-ins to improve the product line. We are upgrading our recommendation to a HOLD now that we are gaining additional visibility into the company’s future."
For an analyst ratings summary and ratings history on AngioDynamics click here. For more ratings news on AngioDynamics click here.
Shares of AngioDynamics closed at $12.96 yesterday.
Analyst, Jeff Jonas, said, "Angiodynamics announced plans to acquire Navilyst Medical for $372 million in cash and stock...The combined company will once again move to separate vascular and peripheral salesforces, allowing each to focus on a smaller number of products and call points...However, Navilyst has seen little or no revenue growth recently, as price and volume pressure in fluid management (61% of sales) offsets growth in vascular access (39%)."
"Overall we think this is a strategic and accretive deal for ANGO. This deal also more than offsets the loss of the LC Bead distribution agreement and does not preclude the company from future tuck-ins to improve the product line. We are upgrading our recommendation to a HOLD now that we are gaining additional visibility into the company’s future."
For an analyst ratings summary and ratings history on AngioDynamics click here. For more ratings news on AngioDynamics click here.
Shares of AngioDynamics closed at $12.96 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades Serve Robotics (SERV) to Buy
- Jefferies Upgrades Minerva Neurosciences (NERV) to Buy
- Stifel Upgrades Intuitive Machines Inc. (LUNR) to Buy
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
